Document is current
Any future updates will be listed below
-
Authors
Kamel, Hooman https://orcid.org/0000-0002-5745-0307
Riley, Laura E.
Son, Moeun
Karas, Maria G.
Roman, Mary J. https://orcid.org/0000-0003-0183-6769
De Sancho, Maria T.
Fink, Matthew E.
Liberman, Ava L.
Navi, Babak B.
- License Information
-
More Information
Article History
Received: 2 September 2025
Accepted: 16 April 2026
First Online: 18 May 2026
Competing interests
: Hooman Kamel reports a Deputy Editor role for JAMA Neurology ; clinical trial steering/executive committee roles for the LIBREXIA-AF (Janssen) trial, INTERCEPT (World Health Research Institute and Javelin) trial, and LAAOS-4 (Population Health Research Institute and Boston Scientific) trial; consulting or endpoint adjudication committee roles for AbbVie, Alnylam, Arthrosi, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Medtronic, Novartis, and Novo Nordisk; and ownership interests in Ascential Technologies, Doug Labs, and TETmedical. Mary J. Roman reports research funding from the Vital Projects Fund. Maria T. De Sancho reports honoraria from Pharmacosmos. Matthew E. Fink reports an Editor role for Neurology Alert . Ava L. Liberman reports a role on the data and safety monitoring board for Shionogi. The remaining authors declare no competing interests.
